$ZOM
Zomedica Corp.

2016 Q4 Form 10-K Financial Statement

#000117184318001549 Filed on February 28, 2018

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.380M $620.0K $4.162M
YoY Change 11800.0% 7302.42%
% of Gross Profit
Research & Development $580.0K $410.0K $1.519M
YoY Change
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $43.13K
YoY Change
% of Gross Profit
Operating Expenses $2.690M $1.040M $1.519M
YoY Change 13350.0% 2601.06%
Operating Profit -$5.726M
YoY Change
Interest Expense -$10.00K $0.00 -$14.30K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$280.0K
YoY Change
Pretax Income -$2.700M -$1.040M -$5.740M
YoY Change 13400.0% 10110.4%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.700M -$1.040M -$5.740M
YoY Change 13400.0% 10110.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$32.45K -$13.14K -$71.61K
COMMON SHARES
Basic Shares Outstanding 80.16M
Diluted Shares Outstanding 80.16M

Balance Sheet

Concept 2016 Q4 2016 Q3 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.230M $3.860M $3.227M
YoY Change 2836.36% 3116.67% 3708.42%
Cash & Equivalents $3.227M $3.860M $3.227M
Short-Term Investments
Other Short-Term Assets $330.0K $240.0K $332.6K
YoY Change
Inventory
Prepaid Expenses
Receivables $18.92K $10.00K $18.92K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.578M $4.110M $3.578M
YoY Change 3152.92% 3325.0% 4123.32%
LONG-TERM ASSETS
Property, Plant & Equipment $289.0K $290.0K $289.0K
YoY Change
Goodwill
YoY Change
Intangibles $17.94K
YoY Change
Long-Term Investments
YoY Change
Other Assets $690.0K $690.0K $690.4K
YoY Change
Total Long-Term Assets $997.3K $1.300M $1.297M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.578M $4.110M $3.578M
Total Long-Term Assets $997.3K $1.300M $1.297M
Total Assets $4.576M $5.410M $4.876M
YoY Change 4059.6% 4408.33% 5654.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $730.0K $470.0K $734.4K
YoY Change 3550.0% 11093.87%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $741.2K $470.0K $734.4K
YoY Change 3605.79% 11093.87%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $6.730K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.00K $10.00K $6.730K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $741.2K $470.0K $734.4K
Total Long-Term Liabilities $10.00K $10.00K $6.730K
Total Liabilities $740.0K $480.0K $741.2K
YoY Change 3600.0% 11196.45%
SHAREHOLDERS EQUITY
Retained Earnings -$7.561M
YoY Change
Common Stock $10.19M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.834M $4.940M $4.134M
YoY Change
Total Liabilities & Shareholders Equity $4.576M $5.410M $4.876M
YoY Change 4059.6% 4408.33% 5654.57%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2016
OPERATING ACTIVITIES
Net Income -$2.700M -$1.040M -$5.740M
YoY Change 13400.0% 10110.4%
Depreciation, Depletion And Amortization $10.00K $10.00K $43.13K
YoY Change
Cash From Operating Activities -$1.480M -$1.640M -$4.562M
YoY Change 16300.0% 8767.19%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$130.0K $231.6K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$130.0K -$241.2K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $880.1K $3.876M $4.756M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 860.0K 3.900M 4.786M
YoY Change
NET CHANGE
Cash From Operating Activities -1.480M -1.640M -4.562M
Cash From Investing Activities -10.00K -130.0K -241.2K
Cash From Financing Activities 860.0K 3.900M 4.786M
Net Change In Cash -630.0K 2.130M -17.03K
YoY Change -21400.0% -66.9%
FREE CASH FLOW
Cash From Operating Activities -$1.480M -$1.640M -$4.562M
Capital Expenditures -$10.00K -$130.0K $231.6K
Free Cash Flow -$1.470M -$1.510M -$4.794M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Document Type
DocumentType
10-K
CY2017Q2 dei Entity Public Float
EntityPublicFloat
67200000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
828737
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
734431
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
828737
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
734431
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28272
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18921
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5998
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49129
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
138742
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1768526
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1205456
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1467934
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
849679
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
849679
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1467934
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2797
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2690
CY2017Q4 us-gaap Assets
Assets
5215822
CY2017 dei Trading Symbol
TradingSymbol
zom
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Registrant Name
EntityRegistrantName
Zomedica Pharmaceuticals Corp.
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
90449869
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001684144
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016Q4 us-gaap Assets
Assets
4575558
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4262692
CY2016Q4 us-gaap Assets Current
AssetsCurrent
3578212
CY2017 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Basis of preparation</div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting policies set out below have been applied consistently in the consolidated financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, ZoMedica Pharmaceuticals Inc.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All inter-company accounts and transactions have been eliminated on consolidation.</div></div>
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3226680
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3243710
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3448147
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
221467
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17030
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2017 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2016 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90225869
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83964569
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90225869
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83964569
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
18244659
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
10189973
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
6726
CY2017Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
CY2016Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
6726
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
57370
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
60200
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
90
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
104340
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3400560
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2053960
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
157920
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
89970
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23120
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3343190
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1993760
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
520
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
57370
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
59680
CY2017 us-gaap Depreciation
Depreciation
89613
CY2016 us-gaap Depreciation
Depreciation
43131
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43131
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89613
CY2017 us-gaap Depreciation Nonproduction
DepreciationNonproduction
89613
CY2016 us-gaap Depreciation Nonproduction
DepreciationNonproduction
43131
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
751
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3441
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6238
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11768
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17938
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15141
CY2016 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
9611
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
13978
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14296
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3946270
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2916604
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6570000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4755586
CY2017 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-6726
CY2016 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
2013
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8065072
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5740492
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1430420
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1357170
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
808260
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-43960
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-297460
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-162210
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2177570
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1549930
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
236350
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
398930
CY2017 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
9351
CY2016 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
21031
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
94306
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
552608
CY2017 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
124977
CY2016 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
890142
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
205143
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7393
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
979522
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35423
CY2017 us-gaap Professional Fees
ProfessionalFees
1294044
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17938
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15141
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
275131
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
15741
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5215822
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4575558
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
828737
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
741157
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7486220
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4786353
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171736
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-241215
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7093017
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4562168
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-8065072
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-5740492
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-8084050
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-5726196
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
34784
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
34784
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2016Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
29310
CY2016Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
8706
CY2017Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
32754
CY2017Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
23822
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
56576
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
115635
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9611
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
171736
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231604
CY2017Q4 us-gaap Prepaid Rent
PrepaidRent
155220
CY2016Q4 us-gaap Prepaid Rent
PrepaidRent
160395
CY2016Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3875500
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
880086
CY2017Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3250000
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3320000
CY2016 us-gaap Professional Fees
ProfessionalFees
1245182
CY2016 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
231604
CY2017 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
171736
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
106559
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
338163
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
509899
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
289034
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
371157
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2751326
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1518589
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15626100
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7561028
CY2016Q4 us-gaap Share Price
SharePrice
1.45
CY2017Q1 us-gaap Share Price
SharePrice
1.35
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y21D
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.25
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.50
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
849679
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1467934
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.25
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.50
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.50
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.63
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.63
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.59
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0056
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0112
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1815000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7375000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3500000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3875000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
535000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1280000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
200000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7975000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8080000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.05
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.84
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2016Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.05
CY2017Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2017Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.05
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.25
CY2016Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.50
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.50
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.75
CY2016Q1 us-gaap Share Price
SharePrice
0.20
CY2016Q2 us-gaap Share Price
SharePrice
0.20
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2017Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
43613
CY2017Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
112314
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1700000
CY2016Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
480000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
400000
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7060
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
220000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7940
CY2017Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
45000
CY2017Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
230131
CY2016 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15741
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
275131
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35423
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
979522
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
3414045
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3834401
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
4387085
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-style: italic;">Use of estimates</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.</div></div></div></div></div>
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87400255
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80158312
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87400255
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80158312
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87400255
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80158312
CY2016 zom Adjustments To Additional Paid In Capital Recapitalization Excess Of Purchase Price Over Net Asset Value
AdjustmentsToAdditionalPaidInCapitalRecapitalizationExcessOfPurchasePriceOverNetAssetValue
272354
CY2017Q4 zom Deferred Tax Assets Investment Tax Credit
DeferredTaxAssetsInvestmentTaxCredit
87200
CY2016Q4 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2016Q4 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2016Q4 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2016Q4 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
828737
CY2016Q4 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
734431
CY2017Q4 zom Contractual Financial Liabilities
ContractualFinancialLiabilities
828737
CY2016Q4 zom Contractual Financial Liabilities
ContractualFinancialLiabilities
741157
CY2017Q4 zom Contractual Financial Liabilities Maturity3 To6 Months
ContractualFinancialLiabilitiesMaturity3To6Months
CY2016Q4 zom Contractual Financial Liabilities Maturity3 To6 Months
ContractualFinancialLiabilitiesMaturity3To6Months
CY2017Q4 zom Contractual Financial Liabilities Maturity6 To9 Months
ContractualFinancialLiabilitiesMaturity6To9Months
CY2016Q4 zom Contractual Financial Liabilities Maturity6 To9 Months
ContractualFinancialLiabilitiesMaturity6To9Months
CY2017Q4 zom Contractual Financial Liabilities Maturity9 To12 Months
ContractualFinancialLiabilitiesMaturity9To12Months
CY2016Q4 zom Contractual Financial Liabilities Maturity9 To12 Months
ContractualFinancialLiabilitiesMaturity9To12Months
CY2017Q4 zom Contractual Financial Liabilities Maturity Greater Than1 Year
ContractualFinancialLiabilitiesMaturityGreaterThan1Year
CY2016Q4 zom Contractual Financial Liabilities Maturity Greater Than1 Year
ContractualFinancialLiabilitiesMaturityGreaterThan1Year
CY2017Q4 zom Contractual Financial Liabilities Maturity Less Than3 Months
ContractualFinancialLiabilitiesMaturityLessThan3Months
828737
CY2016Q4 zom Contractual Financial Liabilities Maturity Less Than3 Months
ContractualFinancialLiabilitiesMaturityLessThan3Months
741157
CY2017Q4 zom Deferred Tax Assets Intangible Assets Transferred On Amalgamation
DeferredTaxAssetsIntangibleAssetsTransferredOnAmalgamation
CY2016Q4 zom Deferred Tax Assets Intangible Assets Transferred On Amalgamation
DeferredTaxAssetsIntangibleAssetsTransferredOnAmalgamation
14980
CY2016Q4 zom Deferred Tax Assets Investment Tax Credit
DeferredTaxAssetsInvestmentTaxCredit
42200
CY2017Q4 zom Deferred Tax Assets Schedule13 Reserves
DeferredTaxAssetsSchedule13Reserves
14030
CY2016Q4 zom Deferred Tax Assets Schedule13 Reserves
DeferredTaxAssetsSchedule13Reserves
7760
CY2017Q4 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2016Q4 zom Due To Related Parties3 To6 Months
DueToRelatedParties3To6Months
CY2017Q4 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2016Q4 zom Due To Related Parties6 To9 Months
DueToRelatedParties6To9Months
CY2017Q4 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2016Q4 zom Due To Related Parties9 To12 Months
DueToRelatedParties9To12Months
CY2017Q4 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2016Q4 zom Due To Related Parties Greater Than1 Year
DueToRelatedPartiesGreaterThan1Year
CY2017Q4 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
CY2016Q4 zom Due To Related Parties Less Than3 Months
DueToRelatedPartiesLessThan3Months
6726
CY2017 zom Effective Income Tax Rate Reconciliation Combined Federal And Provincial Statutory Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationCombinedFederalAndProvincialStatutoryIncomeTaxRatePercent
0.27
CY2016 zom Effective Income Tax Rate Reconciliation Combined Federal And Provincial Statutory Income Tax Rate Percent
EffectiveIncomeTaxRateReconciliationCombinedFederalAndProvincialStatutoryIncomeTaxRatePercent
0.27
CY2017Q1 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
5000
CY2017 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
5000
CY2016 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
CY2017Q4 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
786273
CY2016Q4 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
332611
CY2017Q4 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
566832
CY2016Q4 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
690374
CY2016Q3 zom Prepaid Rent Current And Noncurrent
PrepaidRentCurrentAndNoncurrent
801973
CY2017 zom Proceeds From Amalgamation
ProceedsFromAmalgamation
CY2016 zom Proceeds From Amalgamation
ProceedsFromAmalgamation
108966
CY2016Q2 zom Qualifying Transaction Common Stock Issued Share
QualifyingTransactionCommonStockIssuedShare
1900000
CY2016Q2 zom Qualifying Transaction Common Stock Issued Value
QualifyingTransactionCommonStockIssuedValue
475000
CY2016Q2 zom Qualifying Transaction Common Stock Issued Value
QualifyingTransactionCommonStockIssuedValue
373207
CY2016Q2 zom Qualifying Transaction Elimination Contributed Surplus
QualifyingTransactionEliminationContributedSurplus
32467
CY2016Q2 zom Qualifying Transaction Elimination Deficit
QualifyingTransactionEliminationDeficit
232984
CY2016Q2 zom Qualifying Transaction Elimination Share Capital
QualifyingTransactionEliminationShareCapital
309589
CY2016Q2 zom Qualifying Transaction Equity Interests Issued
QualifyingTransactionEquityInterestsIssued
477737
CY2016Q2 zom Qualifying Transaction Equity Interests Issued
QualifyingTransactionEquityInterestsIssued
375265
CY2016Q2 zom Qualifying Transaction Excess Purchase Price Over Net Asset Value
QualifyingTransactionExcessPurchasePriceOverNetAssetValue
346757
CY2016Q2 zom Qualifying Transaction Excess Purchase Price Over Net Asset Value
QualifyingTransactionExcessPurchasePriceOverNetAssetValue
272354
CY2016Q2 zom Qualifying Transaction Options Issued Share
QualifyingTransactionOptionsIssuedShare
80000
CY2016Q2 zom Qualifying Transaction Options Issued Value
QualifyingTransactionOptionsIssuedValue
2737
CY2016Q2 zom Qualifying Transaction Options Issued Value
QualifyingTransactionOptionsIssuedValue
2058
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Liabilities
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities
102485
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Liabilities
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities
80522
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Cash
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash
138687
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Cash
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCash
108966
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Prepaid Fees
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidFees
94778
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Prepaid Fees
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidFees
74467
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
477737
CY2016Q2 zom Qualifying Transaction Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
QualifyingTransactionRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
375265
CY2017Q1 zom Settlement Of Liabilities Amout
SettlementOfLiabilitiesAmout
50000
CY2016Q1 zom Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
CY2017Q1 zom Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
CY2016Q2 zom Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Issued Through Amalgamation
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsIssuedThroughAmalgamation
80000
zom Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Issued Through Amalgamation
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsIssuedThroughAmalgamation
80000
zom Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Issued Through Amalgamation Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsIssuedThroughAmalgamationWeightedAverageExercisePrice
0.25
CY2016Q3 zom Stock Issued During Period Shares Issued For Financing Net Of Cost
StockIssuedDuringPeriodSharesIssuedForFinancingNetOfCost
3342480
CY2016Q4 zom Stock Issued During Period Shares Issued For Financing Net Of Cost
StockIssuedDuringPeriodSharesIssuedForFinancingNetOfCost
791373
CY2017Q2 zom Stock Issued During Period Shares Issued For Financing Net Of Cost
StockIssuedDuringPeriodSharesIssuedForFinancingNetOfCost
2902682
CY2017Q3 zom Stock Issued During Period Shares Issued For Financing Net Of Cost
StockIssuedDuringPeriodSharesIssuedForFinancingNetOfCost
1502691
CY2016 zom Stock Issued During Period Value Issued Due To Recapitalization Net Of Cost
StockIssuedDuringPeriodValueIssuedDueToRecapitalizationNetOfCost
196534
CY2016 zom Stock Issued During Period Value Issued For Financing Net Of Cost
StockIssuedDuringPeriodValueIssuedForFinancingNetOfCost
4717570
CY2017 zom Stock Issued During Period Value Issued For Financing Net Of Cost
StockIssuedDuringPeriodValueIssuedForFinancingNetOfCost
6513424

Files In Submission

Name View Source Status
0001171843-18-001549-index-headers.html Edgar Link pending
0001171843-18-001549-index.html Edgar Link pending
0001171843-18-001549.txt Edgar Link pending
0001171843-18-001549-xbrl.zip Edgar Link pending
exh_1023.htm Edgar Link pending
exh_231.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10kp13.jpg Edgar Link pending
f10kp8.jpg Edgar Link pending
f10k_022818p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mnp.jpg Edgar Link pending
mnp_footer.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20171231.xml Edgar Link completed
zom-20171231.xsd Edgar Link pending
zom-20171231_cal.xml Edgar Link unprocessable
zom-20171231_def.xml Edgar Link unprocessable
zom-20171231_lab.xml Edgar Link unprocessable
zom-20171231_pre.xml Edgar Link unprocessable